A year of significant policy change at the FDA brought momentum and scrutiny into the new year. As 2026 gets underway, biopharma companies are responding to sweeping vaccine changes while concerns ...
The FDA announced it planned to restrict use of GLP-1 active pharmaceutical ingredients in non-FDA-approved drugs, including those from Hims & Hers and other compounding pharmacies.“These actions are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results